In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

COMPASS Trial - Bleeding and cancer risk in patients with vascular disease treated with Rivaroxaban

Session Clinical Trial Updates

Speaker John William Eikelboom

Congress : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Secondary Prevention
  • Session type : Late-Breaking Science
  • FP Number : 1321
15 views
15 views

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Other presentations from this session

Clinical Trial Updates

  • ESC Congress 2018
  • Other
  • Late-Breaking Science
  • 26 August 2018
  • 11:00 - 12:30
session 2018 2018
12

Other presentations from this speaker

John William Eikelboom speaker

John William Eikelboom

Practitioner (Specialist Physician/Researcher/Staff member or other), McMaster University,Hamilton (Canada)

29


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are